Viking gains on Phase II NAFLD data
Viking Therapeutics Inc. (NASDAQ:VKTX) added $9.07 (87%) to $19.46 on Tuesday after reporting that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease. The move translates to a gain in market cap of over $550 million.
The company plans to meet with FDA early next year to discuss next steps for the liver-selective thyroid hormone receptor β agonist. On a conference call, Viking said it expects FDA will also require biopsy data from an additional Phase II trial before it can move to Phase III testing...
BCIQ Company Profiles
BCIQ Target Profiles